Curated News
By: NewsRamp Editorial Staff
May 12, 2026

Tonix Reports Q1 2026 Results, TONMYA Momentum Grows

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Tonix's TONMYA, the first new fibromyalgia drug in 15 years, expands managed care coverage to 35M lives, boosting market advantage.
  • Tonix reports Q1 2026 results: TONMYA prescriptions grow since Nov 2025 launch, Phase 1 data for TNX-4800 positive, Phase 2 for depression planned.
  • Tonix's new fibromyalgia treatment TONMYA and Lyme disease prevention candidate TNX-4800 address high unmet medical needs, improving patients' lives.
  • Tonix's TONMYA is the first new fibromyalgia medicine in 15 years, and they're also testing it for major depressive disorder.

Impact - Why it Matters

The success of TONMYA and the expansion of its managed care coverage are critical for fibromyalgia patients who have had limited treatment options for 15 years. This news also signals potential breakthroughs in Lyme disease prevention and new applications for TONMYA in major depressive disorder, which could address major public health challenges. Investors should note the commercial traction and pipeline progress as key indicators of Tonix's growth trajectory.

Summary

Tonix Pharmaceuticals (NASDAQ: TNXP) has announced its first-quarter 2026 financial results, highlighting significant commercial progress for TONMYA, its recently launched fibromyalgia treatment, and ongoing advancements across its clinical pipeline. TONMYA, the first new fibromyalgia medicine in 15 years, has shown impressive growth in prescriptions, prescribers, refills, and patient access since its November 2025 launch. The company also recently announced a managed care agreement that expands potential coverage to approximately 35 million U.S. commercial lives, significantly broadening patient access. Additionally, pipeline updates include positive Phase 1 data for TNX-4800, a Lyme disease prevention candidate, and plans to initiate a Phase 2 study of TONMYA in major depressive disorder later this year. These developments underscore Tonix's commitment to addressing high unmet medical needs in central nervous system (CNS) and immunology treatments.

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on CNS and immunology therapies in areas of high unmet need. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) represents the first new fibromyalgia treatment in over 15 years. The company’s CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace SymTouch and Tosymra. Tonix is also maximizing the science behind TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder. Beyond CNS, the pipeline includes TNX-2900 (Phase 2 ready for Prader-Willi syndrome) and immunology programs such as monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. For more details, visit the full press release at https://ibn.fm/oVPHY.

BioMedWire, a specialized communications platform under the Dynamic Brand Portfolio @ IBN, covers the latest in Biotech, BioMed, and Life Sciences. The platform provides access to a vast network of wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, enhanced press release distribution, and social media reach to millions. For continuous updates on TNXP, visit the company’s newsroom at https://ibn.fm/TNXP.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Reports Q1 2026 Results, TONMYA Momentum Grows

blockchain registration record for this content.